The mobile frequency technology provider added $13.7m to an SBA Communications and American Tower-backed round now sized at $64.7m.

Boehringer Ingelheim Venture Fund co-led the cancer immunotherapy developer's series A round, which also featured Illumina Ventures.

Repeatome drug developer Rome Therapeutics is based on intellectual property from Massachusetts General Hospital and Icahn School of Medicine at Mount Sinai.

JHU-founded restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The potential acquisition would reportedly value the HPE, Microsoft and Koch-backed cloud software provider below its most recent valuation but above $250m.

Medytox-backed restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.

Repeatome drug developer Rome Therapeutics was incubated within GV, which took part in the series A round along with fellow corporate unit Partners Innovation Fund.

The robotics AI technology developer pulled in $36m through a series D round led by SoftBank Vision Fund that included fellow existing investor Qualcomm Ventures.

Terese Hougaard has taken a principal role at the UK-based venture firm after five years at Alphabet unit CapitalG, most recently as a partner.